Allergan the pioneers of BOTOX®, have shown further investment in medical science with their recent investment of a clinical stage biopharmaceutical company developing a topical neurotoxin.
“The acquisition of Anterios bolsters Allergan’s commitment to innovation and maintaining its leadership position in neurotoxin development and commercialization,” said David Nicholson, Executive Vice President and President, Global Brands Research & Development at Allergan.
Read the full story here.